Found 448 results in Expert Content

How can decisions made during the preclinical phase of drug development increase the chances of a product’s eventual success in a difficult marketplace?

Summary: Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes.

Get insights on using lipid systems during early development to achieve successful formulation and patient outcomes

Catalent’s experts presented technical posters on advanced drug design, discovery, development, delivery, packaging and scale-up. Click here to download [Part 1] of the 2015 AAPS posters Click here to...

Catalent with deep scientific expertise has the broadest capabilies and advancved technologies for controlled and modified release products.

This eBook published by Pharmaceutical Technology provides an overview of the regulatory landscape related to elemental impurities testing, discusses the challenges of implementing ICH Q3D guidelines ...

You will learn about a pharmaceutical company who was interested in scaling-up a multi-particulate, modified-release product to a commercial scale using fluid bed bottom-spray (Wurster) coating.

Summary: Given the accelerated timelines associated with expedited programs, lipid-based drug formulations, encapsulated in softgel capsules, provide an attractive option for addressing the challenges...

Summary: Learn about the end-to-end capabilities of Catalent’s inhalation network, supporting the development and manufacture of formulations delivered by Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs) and unit- or bi-dose nasal sprays.

Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions